Citius Pharmaceuticals earnings release, August 14, 2026

Citius Pharmaceuticals, Inc. (CTXR) · Form 8-K, Item 2.02 · Filed · SEC filing

Citius

Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1

Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR®

$17 million in cash and cash equivalents as of June 30, 2026

Expanded

LYMPHIR commercial and medical affairs organizations deployed nationwide

CRANFORD,

N.J., August 14, 2026 – Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

“The

LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers,

NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR’s differentiated clinical profile,” said Leonard Mazur, Chairman and Chief

Executive Officer of Citius Pharma and Citius Oncology.

“Following the quarter end, we completed the nationwide deployment of Citius Oncology’s expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR’s success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures,” added Mazur.

“We also continued to advance LYMPHIR’s longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT®

& CIBMTR®

Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR’s potential beyond cutaneous

T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR,” concluded Mazur.

Fiscal

Third Quarter 2026 Business Highlights and Subsequent Developments²

Fiscal

Third Quarter 2026 Financial Highlights and Subsequent Developments

About

Citius Pharmaceuticals, Inc.

Citius

Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

About

Citius Oncology, Inc.

Citius

Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius

Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius

Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.³

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended — (Unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Nine Months Ended – June 30, – 2026Nine Months Ended – June 30, – 2025
Revenues1,493,788$—7,105,197$—
Cost of revenues-491,843-1,609,929
Gross Profit1,001,9455,495,268
Operating ExpensesResearch and development1,053,8691,621,3254,287,1067,514,888
Operating ExpensesAmortization of in-process research and development1,720,3124,014,062
Operating ExpensesGeneral and administrative6,149,1734,447,00838,261,00114,626,882
Operating ExpensesStock-based compensation – general and administrative3,810,6652,719,67411,879,1677,946,529
Operating ExpensesTotal Operating Expenses12,734,0198,788,00758,441,33630,088,299
Operating ExpensesOperating Loss-11,732,074-8,788,007-52,946,068-30,088,299
Other Income (Expense)Interest income116,69120,637215,37256,658
Other Income (Expense)Gain on sale of New Jersey net operating losses3,833,277
Other Income (Expense)Amortization of deferred financing costs-179,492-179,492
Other Income (Expense)Interest expense-231,732-172,262-420,301-172,262
Other Income (Expense)Total Other Income (Expense), Net-294,533-151,6253,448,856-115,604
Other Income (Expense)Loss before Income Taxes-12,026,607-8,939,632-49,497,212-30,203,903
Other Income (Expense)Income tax expense (benefit)-107,347264,240-74,317792,720
Other Income (Expense)Net Loss-11,919,260-9,203,872-49,422,895-30,996,623
Other Income (Expense)Net loss attributable to non-controlling interest3,056,417414,00011,108,1271,522,000
Other Income (Expense)Net loss applicable to common stockholders-8,862,843-8,789,872-38,314,768-29,474,623
Other Income (Expense)Net Loss Per Share - Basic and Diluted-0.34-0.8-1.64-3.27
Weighted Average Common Shares OutstandingBasic and diluted (includes pre-funded warrants)26,169,58911,006,89623,343,8699,020,356

Balance Sheet

September 30, — (Unaudited)

June 30, – 2026September 30, – 2025
Current Assets:Cash and cash equivalents17,007,5234,252,290
Current Assets:Accounts receivable, net of allowances686,235
Current Assets:Inventory22,625,94522,286,693
Current Assets:Prepaid expenses3,011,6601,395,490
Current Assets:Total Current Assets43,331,36327,934,473
Current Assets:Operating lease right-of-use asset, net753,039818,694
Current Assets:Deposits38,06238,062
Current Assets:In-process research and development, net of accumulated amortization88,785,93892,800,000
Current Assets:Goodwill9,346,7969,346,796
Current Assets:Total Other Assets98,170,796102,184,858
Current Assets:Total Assets142,255,198130,938,025
Current Liabilities:Accounts payable8,037,89913,693,692
Current Liabilities:License payable15,650,00022,650,000
Current Liabilities:Accrued expenses25,913,9624,190,253
Current Liabilities:Accrued compensation1,871,3203,292,447
Current Liabilities:Note payable1,000,000
Current Liabilities:Operating lease liability176,17088,348
Current Liabilities:Total Current Liabilities51,649,35144,914,740
Current Liabilities:Deferred tax liability7,696,4437,770,760
Current Liabilities:Notes payable, net of deferred financing fees6,410,161
Current Liabilities:Operating lease liability – noncurrent590,787724,925
Current Liabilities:Total Liabilities66,346,74253,410,425
Stockholders’ Equity:Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and 18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively27,45218,068
Stockholders’ Equity:Additional paid-in capital343,704,577306,336,239
Stockholders’ Equity:Accumulated deficit-277,118,897-238,804,129
Stockholders’ Equity:Total Citius Pharmaceuticals, Inc. Stockholders’ Equity66,613,13267,550,178
Stockholders’ Equity:Non-controlling interest9,295,3249,977,422
Stockholders’ Equity:Total Equity75,908,45677,527,600
Stockholders’ Equity:Total Liabilities and Equity142,255,198130,938,025

Cash Flow

(Unaudited)

20262025
Cash Flows From Operating Activities:Net loss-49,422,895-30,996,623
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense11,879,1677,946,529
Adjustments to reconcile net loss to net cash used in operating activities:Issuance of common stock for services107,510
Adjustments to reconcile net loss to net cash used in operating activities:Issuance of common stock warrant68,597
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of in-process research and development4,014,062
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of operating lease right-of-use asset65,655152,212
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of deferred financing costs179,492
Adjustments to reconcile net loss to net cash used in operating activities:Deferred income tax expense (benefit)-74,317792,720
Changes in operating assets and liabilities:Accounts receivable, net of allowances-686,235
Changes in operating assets and liabilities:Inventory-339,252-8,940,201
Changes in operating assets and liabilities:Prepaid expenses-1,616,1701,386,824
Changes in operating assets and liabilities:Accounts payable-5,655,7935,166,831
Changes in operating assets and liabilities:Accrued expenses19,961,2098,506,648
Full release

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as “will,” “anticipate,”

“estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to regain... (truncated) ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain regulatory approval for and commercialize or enter into strategic partnerships with respect to Mino-Lok and Halo-Lido; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange

Commission (“SEC”) filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Pharma’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor

Contact:

Ilanit

Allen ir@citiuspharma.com

908-967-6677 x113

Media

Contact:

STiR-communications

Greg

Salsburg

Greg@STiR-communications.com – Financial Tables Follow –⁴

CITIUS

PHARMACEUTICALS, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Citius Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.